Lung transplantation in children following bone marrow transplantation: A multi-center experience

Division of Pediatric Pulmonology, Miller School of Medicine, University of Miami, Miami, FL, USA.
Pediatric Transplantation (Impact Factor: 1.44). 12/2012; 17(3). DOI: 10.1111/petr.12023
Source: PubMed


Allogenic BMT has been successfully performed as a treatment for hematologic diseases with an expected long-term survival. This survival is truncated by respiratory complications including airway obstruction especially BO. Chronic GVHD has been reported to precede almost all cases reported. LTx has become a therapeutic life-saving option for patients with end-stage lung disease that maybe offered for the treatment of GVHD. We report a multi-center experience of pediatric LTx following BMT in 11 patients age- and gender-matched with 11 controls who received LTx for end-stage lung disease secondary to CF. Overall death was 36.4% over a follow-up period of 19 months (range 3-36 months) for the cases and 27.3% for the control group followed for 17 months (range 8-32 months). Median FEV(1) one yr post-transplant for the cases was 78% predicted compared with 67.3% predicted for the controls. The median for episodes of infection was comparable at a median of one episode per patient through the entire follow-up period among both groups. Acute rejection episodes were significantly higher in the control group with a median of one episode per patient in the control group compared to none within the cases. Our data suggest that LTx may be a valuable therapeutic option for children with end-stage lung disease post-BMT with comparable survival outcome to that after LTx in children for other indications such as CF. Hospital stay was significantly longer in our case group. Infection rate was comparable between groups albeit type of infection varied. Significantly and of interest is that acute rejection episodes were non-existent in these cases.

Download full-text


Available from: Marc G Schecter, Apr 22, 2015
1 Follower
4 Reads
  • Pediatric Transplantation 02/2013; 17(3). DOI:10.1111/petr.12069 · 1.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hematopoietic stem cell transplantation (HSCT) is an accepted treatment modality for various malignant and non-malignant disorders of the lympho-hematopoietic system. Patient survival rate has increased significantly with the use of this procedure. However, with the increase in disease-free patient survival rates, complications including various organ toxicities are also common. Kidney, liver, lung, heart, and skin are among those solid organs that are commonly affected and frequently lead to organ dysfunction and eventually end-organ disease. Conservative measures may or may not be successful in managing the organ failure in these patients. Solid organ transplantation has been shown to be promising in those patients who fail conservative management. This review will summarize the causes of solid organ (kidney, liver, and lung) dysfunction and the available data on transplantation of these solid organs in post-HSCT recipients.
    Pediatric Nephrology 08/2013; 29(8). DOI:10.1007/s00467-013-2587-4 · 2.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Non-infectious pulmonary complications following hematopoietic stem cell transplantation (HSCT) are major cause of morbidity and mortality with limited treatment options. Lung transplantation (LT) has been rarely reported as a treatment option for selected HSCT recipients with these problems.Objectivedescribe the outcome of HSCT recipients who underwent LTMethods2 cases of LT following HSCT from our institution are presented. Cases reported in literature were identified using English language Pubmed/Medline with keywords hematopoietic stem cell transplantation, bone marrow transplantation or bronchiolitis obliterans cross referenced with lung transplantation. We extracted data on baseline characteristics and survival data following LT.Resultstotal of 84 patients are analyzed. Age at time of LT was median of 22 years (range 1-66). 79 patients were recipients of allogeneic HSCT. The indications for LT were bronchiolitis obliterans syndrome (BOS) (63 patients), pulmonary fibrosis (13 patients), BOS/pulmonary fibrosis (5 patients), and GVHD of lung (3 patients). The median time between HSCT and LT was 52.3 months (range 6-240). The median follow up after LT was 36 months (range 0-168). During this time, BOS was documented in 25 patients. Relapse of hematological malignancy was reported in 2 patients and new malignancy developed in 4 patients. At the end of follow up, 60 patients were alive and 24 patients died. The probability of survival following LT at 24 and 36 months was 0.88 (95% CI 0.78-0.93) and0.79 (95% CI 0.67-0.87), respectively.ConclusionLT is a potential therapeutic option in selected patients with severe chronic pulmonary disease following HSCT. Further studies are needed to determine the appropriate timing and the outcome of this approach.This article is protected by copyright. All rights reserved.
    Clinical Transplantation 04/2014; 28(7). DOI:10.1111/ctr.12378 · 1.52 Impact Factor
Show more